Non-Hodgkin’s lymphoma (NHL) represents a group of cancers that develop in the lymphatic system. Individuals with NHL experience uncontrolled malignant white blood cells, rendering the immune system incapable of effectively fighting off infections. Among all malignant lymphomas, the 90% are composed of NHL, making it among the most prevalent hematological adult cancers (Ekströ Smedby et al., 2008).
NHL is segmented by its histology into B-cell, T-cell, and natural killer lymphocyte lymphoma, with B-cell lymphoma constituting 80─85% of the three subtypes. B-cell lymphoma is distinguished into further subtypes, each of which exhibits its own unique pathology and behavior. Among them, diffuse large B-cell lymphoma (DLBCL) is the most prevalent at 33-51% of cases, followed by follicular lymphoma (FL) at 18-51% of cases. Other common B-cell NHLs include marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL), which compose 10-20% and 4-5% of cases, respectively. Each subtype is characterized by specific segmentations, including the distinction of DLBCL into germinal (GCB) and non-germinal center B-cell (non-GCB), as well as the subclassification of FL by histological features into grades 1,2, and 3 (Shustik et al., 2011; Singh et al., 2020).
NHL is segmented by its histology into B-cell, T-cell, and natural killer lymphocyte lymphoma, with B-cell lymphoma constituting 80─85% of the three subtypes. B-cell lymphoma is distinguished into further subtypes, each of which exhibits its own unique pathology and behavior. Among them, diffuse large B-cell lymphoma (DLBCL) is the most prevalent at 33-51% of cases, followed by follicular lymphoma (FL) at 18-51% of cases. Other common B-cell NHLs include marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL), which compose 10-20% and 4-5% of cases, respectively. Each subtype is characterized by specific segmentations, including the distinction of DLBCL into germinal (GCB) and non-germinal center B-cell (non-GCB), as well as the subclassification of FL by histological features into grades 1,2, and 3 (Shustik et al., 2011; Singh et al., 2020).
Scope
- This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for B-cell NHL in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiology forecast for the diagnosed incident and five-year prevalent cases of B-cell NHL. The diagnosed incident and five-year diagnosed prevalent cases of B-cell NHL are segmented by age (18 years and older), sex, and subtype (DLBCL, FL, MZL, and MCL). Furthermore, diagnosed incident and five-year diagnosed prevalent cases of each subtype are segmented by relevant subtype-specific clinical features, including the distinction between GCB and non-GCB DLBCL, FL grade, bulky and non-bulky disease among stage II FL and MCL cases, and Ann Arbor staging (stages I─IV) for all four subtypes. Finally, five-year diagnosed prevalent cases of all subtypes are segmented into cases that have relapsed and those that are in remission or active.
Reasons to Buy
The B-Cell Non-Hodgkin's Lymphoma Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global B-cell NHL markets.
- Quantify patient populations in the global B-cell NHL markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for B-cell NHL therapeutics in each of the markets covered.
- Understand magnitude of the B-cell NHL population by age, sex, histology, and subtype-specific stage at diagnosis.
Table of Contents
1 B-Cell Non-Hodgkin’s Lymphoma: Executive Summary
2 Epidemiology
3 Appendix
List of Tables
List of Figures
